pp-154 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Diabetic macular oedema (DME); neovascular (wet) age-related macular degeneration; retinal vein occlusion
Clinical stage: Phase 3
Modality: Biologic (anti-VEGF-A mAb conjugated to biopolymer via ABC Platform)
Mechanism / Target: Anti-VEGF-A antibody — blocks VEGF-driven vascular leakage and neovascularisation; biopolymer conjugate increases vitreal half-life enabling extended dosing intervals
Route / form: Intravitreal injection (target: every 4-6 months vs current monthly/bimonthly anti-VEGFs)
Differentiation: Extended dosing interval significantly reduces injection burden; superior VEGF binding kinetics; high intraocular drug levels sustained between injections
Manufacturer #39183
Ophthalmology company developing long-acting retinal therapies to reduce injection burden. Proprietary ABC Platform conjugates anti-VEGF to biopolymers for extended duration of action. Wholly owned Phase 3 pipeline targeting the three major retinal vascular diseases.
None